Geographic atrophy

GA · Ophthalmology · 6 drugs · 3 indications

Advanced dry AMD with retinal cell death.
Competitive Landscape (6 drugs)
DrugCompanyMechanismModalityRouteStage
SefaxersenAZNFactor B inhibitionAntisense oligonucleotideSCPHASE3
gefurulimabAZNC5 inhibitorAntibodySCPHASE3
FabhaltaNVSComplement factor B inhibitorSmall moleculeOralAPPROVED
IzervayALPMYC5 inhibitor (pegylated aptamer)Pegylated aptamerIntravitrealAPPROVED
VeopozREGNC5 inhibitorMonoclonal antibodySCAPPROVED
VOYXACT4578Anti-APRIL Monoclonal AntibodyMonoclonal antibodySCAPPROVED
Indications (3)
Geographic atrophy (complement-mediated)
Veopoz PHASE3
Geographic atrophy secondary to AMD
Izervay APPROVED
IgA Nephropathy
Sefaxersen PHASE3gefurulimab PHASE3Fabhalta APPROVEDVOYXACT APPROVED
Upcoming Catalysts
VOYXACT - IgA Nephropathy - Ph3 - eGFR Confirmatory Data (VISIONARY)CLINICAL
4578Early 2026
Pozelimab+Cemdisiran - gMG - Ph3 Topline (NIMBLE)CLINICAL
REGN2026-2027
Fabhalta - IgAN - Full Approval DataCLINICAL
NVSH2 2026
Data from Supabase · Updated 2026-03-24